Algert Global’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $8.99M | Buy |
1,002,810
+42,753
| +4% | +$383K | 0.19% | 154 |
|
|
2025
Q1 | $7.2M | Buy |
960,057
+234,752
| +32% | +$1.76M | 0.18% | 164 |
|
|
2024
Q4 | $5.45M | Buy |
725,305
+209,096
| +41% | +$1.57M | 0.13% | 261 |
|
|
2024
Q3 | $3.92M | Buy |
516,209
+163,076
| +46% | +$1.24M | 0.11% | 330 |
|
|
2024
Q2 | $2.18M | Buy |
353,133
+55,311
| +19% | +$342K | 0.07% | 444 |
|
|
2024
Q1 | $1.51M | Sell |
297,822
-38,943
| -12% | -$198K | 0.06% | 503 |
|
|
2023
Q4 | $2.02M | Buy |
336,765
+129,670
| +63% | +$777K | 0.08% | 415 |
|
|
2023
Q3 | $1.47M | Sell |
207,095
-84,461
| -29% | -$598K | 0.07% | 467 |
|
|
2023
Q2 | $2.05M | Buy |
291,556
+30,570
| +12% | +$215K | 0.09% | 376 |
|
|
2023
Q1 | $2.18M | Buy |
260,986
+103,042
| +65% | +$860K | 0.1% | 314 |
|
|
2022
Q4 | $1.81M | Buy |
157,944
+60,817
| +63% | +$698K | 0.1% | 325 |
|
|
2022
Q3 | $1.22M | Buy |
97,127
+19,139
| +25% | +$241K | 0.07% | 455 |
|
|
2022
Q2 | $825K | Buy |
77,988
+9,874
| +14% | +$104K | 0.06% | 558 |
|
|
2022
Q1 | $1.11M | Buy |
68,114
+48,058
| +240% | +$782K | 0.07% | 482 |
|
|
2021
Q4 | $278K | Hold |
20,056
| – | – | 0.03% | 760 |
|
|
2021
Q3 | $288K | Buy |
+20,056
| New | +$288K | 0.04% | 774 |
|